A phase III study to access the safety and efficacy of prolgolimab 250 mg fixed dose administered every 3 weeks versus prolgolimab 1 mg/kg every 2 weeks in patients with metastatic... von Demidov, Lev, Kharkevich, Galina, Petenko, Natalia, Moiseenko, Vladimir, Protsenko, Svetlana, Semiglazova, Tatiana, Zimina, Anastasia, Kovalenko, Nadezhda, Fadeeva, Natalia, Kirtbaya, Dmitry, Belogortsev, Igor, Tantsyrev, Denis, Odintsova, Svetlana, Nesterova, Alfia, Vorontsova, Karina, Makarycheva, Yulia, Linkova, Yulia, Zinkina-Orikhan, Arina, Siliutina, Anna, Sorokina, Irina, Liaptseva, Daria, Chistyakov, Vladimir, Lutsky, Anton

Volltext

Real-World Experience with Targeted Therapy in BRAF Mutant Advanced Melanoma Patients: Results from a Multicenter Retrospective Observational Study Advanced Melanoma in Russia (Exp... von Orlova, Kristina V., Ledin, Evgeniy V., Zhukova, Natalia V., Orlova, Rashida V., Karabina, Elena V., Volkonskiy, Mikhail V., Stroyakovskiy, Daniil L., Yurchenkov, Aleksandr N., Protsenko, Svetlana A., Novik, Alexey V., Vorotilina, Ludmila V., Moiseenko, Fedor V., Chang, Victor L., Kazmin, Aleksandr I., Tkachenko, Svetlana A., Gamaunov, Sergey V., Naskhletashvili, David R., Samoylenko, Igor V., Vikhrova, Anastasia S., Utyashev, Igor A., Kharkevich, Galina Yu, Petenko, Natalia N., Shubina, Irina Zh, Demidov, Lev V.

Volltext

Immunological monitoring for prediction of clinical response to antitumor vaccine therapy von Mikhaylova, Irina N, Shubina, Irina Zh, Chkadua, George Z, Petenko, Natalia N, Morozova, Lidia F, Burova, Olga S, Beabelashvili, Robert Sh, Parsunkova, Kermen A, Balatskaya, Natalia V, Chebanov, Dmitrii K, Pospelov, Vadim I, Nazarova, Valeria V, Vihrova, Anastasia S, Cheremushkin, Evgeny A, Molodyk, Alvina A, Kiselevsky, Mikhail V, Demidov, Lev V

Volltext

Combination of encorafenib and binimetinib in the treatment of patients with BRAF-mutated advanced melanoma. Case report von Orlova, Kristina V., Petenko, Natalia N., Garanina, Natalia V., Demidov, Lev V.

Volltext

Recurrence-free survival (RFS) and objective response rate (ORR) phase 1/2 study of intralesional (IL) neoadjuvant (neo) anti-PD1 agents (aPD1) for stage IIIB-IV melanoma (MEL) von Samoylenko, Igor, Korotkova, Olga V., Shakhray, Ekaterina, Zabotina, Tatiana, Berdnikov, Sergey, Tabakov, Dmitry, Zakharova, Elena, Petenko, Natalia N., Demidov, Lev V.

Volltext

Paclitaxel and carboplatin chemotherapy in patients with metaststic melanoma refractory to BRAF/MEK inhibitors von Samoylenko, Igor, Kharkevich, Galina, Petenko, Natalia N., Orlova, Kristina V., Sinelnikov, Igor, Utyashev, Igor A, Vikhrova, Anastasia, Markina, Irina, Demidov, Lev V.

Volltext

Duration of targeted therapy in metastatic renal cell carcinoma patients with ECOG PS>2 von Tsimafeyeu, Ilya, Petenko, Natalia N., Snegovoy, Anton, Varlamov, Sergey, Demidov, Lev V.

Volltext

Phase II, multicenter, uncontrolled trial of single-agent capecitabine in patients with non-clear cell metastatic renal cell carcinoma von Tsimafeyeu, Ilya, Demidov, Lev, Kharkevich, Galina, Petenko, Natalia, Galchenko, Vladimir, Sinelnikov, Igor, Naidzionak, Uladzislau

Volltext

Adjuvant dendritic cell (DC)-based vaccine therapy of melanoma patients von Petenko, Natalia N., Mikhaylova, Irina N., Chkadua, George Z., Baryshnikov, Anatoly Y., Demidov, Lev V.

Volltext

The immunologic patterns of response to immunotherapy von Borunova, Anna A.

Volltext